


# EMV CAPITAL PLC

DEEP TECH | LIFE SCIENCES | SUSTAINABILITY

Virtual Meet the Portfolio  
Deeptech Recycling  
Wanda Health

1 December 2025



# DISCLAIMER

This presentation (and any information contained in any oral presentation accompanying it) (**Presentation**) has been prepared by EMV Capital plc (**Company**). This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (**FSMA**). This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Any person who receives this Presentation should not rely on or act upon it. Any person who is in any doubt about this Presentation should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.

Whilst the information contained in this Presentation has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as **Information**) and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation. All statements of opinion and/or belief contained in this Presentation and all views expressed represent the directors' own current assessment and interpretation of information available to them as at the date of this Presentation.

This Presentation has not been fully or independently verified and is subject to material updating, revision and further amendment. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.

This Presentation contains certain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements include, but are not limited to, statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, growth, forecasts, projections, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Therefore, actual results and future events could differ materially from those anticipated in such statements. No representation is made or assurance given that such statements or views are correct or that the objectives of the Company will be achieved. The reader is cautioned not to place reliance on these statements or views and no responsibility is accepted by the Company or any of its shareholders, directors, officers, agents, employees or advisers in respect thereof.

This Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever.

Neither this Presentation nor any copy of it may be: (a) taken or transmitted into Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or the United States of America (each a **Restricted Territory**), their territories or possessions; (b) distributed to any US person (as defined in Regulation S under the United States Securities Act of 1933 (as amended)); or (c) distributed to any individual outside a Restricted Territory who is a resident thereof, in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this document in or to persons subject to other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.

By accepting receipt or attending any delivery of, or electronically accessing, this Presentation, each recipient agrees to be bound by the above limitations and conditions and, in particular represents, warrants and undertakes to the Company that: (i) they will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose; and (ii) they agree to comply with the contents of this notice.

# INTRODUCTION TO EMV CAPITAL PLC



Vision to be a **leading VC investment group** in the deep tech and life sciences sectors

Started from £12m AUM and 8 companies in 2020



Identifying, investing in, and building **high growth companies** in the UK and internationally



**Over £104m** Assets Under Management (AUM) at 30 June 2025

- £38.6m in direct balance sheet holdings
- £66.1m in managed and third-party holdings



**70** portfolio companies



Building a sustainable platform to reach next milestone of **£200m+ AUM**




EMV Capital Partners Limited

**FCA authorised** fundraising and fund management practices

# OPERATING MODEL: CAPITAL GROWTH

## GROW VALUE OF OUR PORTFOLIO COMPANIES



### VENTURE BUILDING

Selective capital efficient balance sheet investment and in-kind services to capitalise upon value opportunities

### CORPORATE FINANCE

Facilitating and syndicating external funding for portfolio companies to execute growth and development

### PROACTIVE MANAGEMENT

Proactive engagement with company Boards and co-investors – protecting value and driving for returns

### VALUE CREATION SERVICES

Supporting a cohort of companies in protecting value and value growth

Support includes investment and exit readiness, business and financial strategy, leadership buildout, corporate collaborations

### ROUTES TO EXIT

Proactive drive towards profitable cash exits (partial or full)

To deliver capital gains and carried interest from exits

# EMV CAPITAL PORTFOLIO

## DEEP TECH, LIFE SCIENCES, SUSTAINABILITY



Medical biomarker,  
late clinical



Recycling of plastic  
waste, industrial



Lab technology,  
pre-sales



Regenerative medicine,  
early clinical



Liver cancer  
diagnostics,  
late clinical



Wearable gut monitor,  
early clinical



Portfolio of 50+  
companies managed  
by EMV Capital



Immuno-oncology,  
NASDAQ-listed, late  
clinical



Smart building  
automation, sales



Respiratory  
diagnostics, sales



Robotics, Construction  
Tech, sales



Medical diagnostics,  
late clinical



Waste anaesthetic,  
sales



Semiconductors  
satellite coms, early  
sales



Heat pump,  
development Passive  
ventilation, sales



Liquid biopsy  
oncology, sales



Digital health  
monitoring, sales




AMR/ Infection  
prevention

# MARTLET CAPITAL PORTFOLIO



DISCRETIONARY FUND MANAGER TO CAMBRIDGE-BASED VC FUND



# EMVC VENTURE BUILD PROGRAMME: *DRIVING VALUE AND SHAREHOLDER RETURNS*

## Approach

- Target IP-rich companies needing strategic direction
- Working within large/growing markets
- Restructure via direct equity (cash and/or in-kind services)
- Deploy EMV Capital shares where appropriate

## Growth Support

- Syndicated third-party capital
- Value creation services (commercial, operational, exit-readiness)
- Help companies 'graduate' to access growth capital



**Plastic Waste  
Chemical Recycling**

**FV stake increase of  
£2.5m**

17.5% direct, 27.3%  
advised



**Digital health  
monitoring**

**FV stake increase of £1.4m**

14.4% direct, 21.3%  
advised

**Capital efficient model with strong embedded upside**



# MAKING PLASTIC A MORE SUSTAINABLE MATERIAL

Introduction to DeepTech Recycling  
01 December 2025



[www.deeptech-recycling.co.uk](http://www.deeptech-recycling.co.uk)


# Plastic demand continues to grow but today's plastic value chain is linear with minimal recycling.

90%+ of current plastic waste is not recycled

## Global plastic use will continue to skyrocket

### Plastics use projections

Million tonnes (Mt), projections from 2022



## Global polymer flows in tonnes (OECD 2022 Report)

<b>460 Mt</b> Plastic production and use	<b>353 Mt</b> Plastic waste generated	<b>9%</b> Recycled
<b>49%</b> Landfilled	<b>19%</b> Incinerated	<b>23%</b> Mismanaged, littered and dumped


323 Mt p.a. plastic waste problem and opportunity for investment in recycling infrastructure (based on 2019 plastic flows).

### Sources

OECD: Policy Scenarios for eliminating plastic pollution by 2040 (2024); Plastics Europe: Plastics: The Facts (2020); 1950 – 2019 production data from Plastics Europe; 2050 projection from McKinsey & Co: How plastics waste recycling could transform the chemicals industry (2018); McKinsey & Co: How plastics-waste recycling could transform the chemical industry (2018); OECD: Global Plastic Outlook (2022); Plastics Europe: The Circular Economy for Plastics: European Analysis (2024)

## Huge opportunity for recycling infrastructure to address the growing global need for sustainable polymer supply

### Global polymer demand 2030-2040<sup>1</sup> (Million metric tonnes per year)



### Projected required investment in advanced recycling infrastructure to satisfy global polymer demand

**\$40B+** During 2030s      **\$90B+** During 2040s

From nearly zero in 2020

<sup>1</sup> Polymer demand includes fibres (polyesters and polyamide), excludes rubbers and intermediates.

<sup>2</sup> Figures may not sum to 100%, because of rounding.

<sup>3</sup> Assumes capital intensity range of \$1,500 to \$3,000 per ton.

Source: McKinsey & Co: Advanced recycling: Opportunities for growth (2022)

## Chemical recycling is the solution and an emerging sector, delivering the circular economy

DeepTech Recycling has one of the leading technologies for chemical recycling of plastic waste


### A unique technology platform

DeepTech Recycling has a unique proprietary and patented chemical recycling technology that converts hard-to-recycle plastic waste into **valuable synthetic oil and wax products – Plaxx®**.

Plaxx® can be sold back into the petro-chemical industry as a **“premium green” product**, for the production of virgin quality plastics and other chemicals.



# Clear and comprehensive 3-steps to market leadership



## Strong pipeline of revenue generating commercial projects progressing quickly to execution exemplified below



### Project 1 (Norway)

£22M project with Norwegian Partners.

9,000 t.p.a. commercial plant.

c.£11m debt financing secured from the Norwegian Government.



### Project 2 (Norway)

£5M project with established Waste Management Company and Norwegian Partners.

700 t.p.a. commercial demonstrator for mixed plastic waste.

LOI signed with partners.



### Project 3 (UK)

£20M project with leading packaging producer in the UK and European markets.

Proof-of-concept and feasibility studies successfully completed.

Next stage in progress.



### Project 4

Project with leading European EPS producer.

Initial proof-of-concept testing successfully completed.

Joint IP and development testing in progress

Foundation in place for full commercial deployment by 2027 with multiple projects at various stages of development and strategic partners

## Strong revenue growth projections from pipeline

Underpinned by an efficient and resilient business model


Projected revenues from current pipeline of projects, **c.£1M+ in 2026.**

Projected to be **cash positive during 2027** and exponential growth thereafter.

### Multiple revenue streams

(What we sell)

- Technology Package (IP and know-how)
- Front-End Engineering Services (including Site Selection and Permitting)
- Licenses and Royalties
- Build / Construction Phase Support Services
- Operations Support Services, Training, Certification, Remote Monitoring



## The team



### Marvine Besong

#### Managing Director & CTO

Marvine has been developing and commercialising technology for chemical recycling of plastic waste for a decade. Before joining DeepTech Recycling Ltd he was the Technical Director at Recycling Technologies Ltd.



### Simon Ashby-Rudd

#### Chairman of the Board

Simon has extensive experience in the energy sector with over 30 years in energy investment banking roles at corporations like Dresden Kleinwort Benson, Citigroup, Standard Bank, Tristone Capital and Waterous & Co.



### Dr. Ilian Iliev

#### Investment Director

Ilian is the CEO of EMV Capital PLC, an investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies.



### John Clarkson

#### Strategy Director (NED)

John was the Chair of Recycling Technologies Ltd between 2013 & 2017. He recently stepped down from his position as Executive Chair of NetScientific Plc to concentrate on a few selected companies, in particular DeepTech Recycling.



### Stephen Crowe

#### Interim CFO

Stephen is the CFO of EMV Capital Plc. He is a commercial, growth-focused and highly experienced Finance Leader with over 20+ years of experience in a wide range of financial institutions. He is a qualified chartered accountant.



### Prof. Jonathan Seville

#### Technical Adviser

Jonathan was previously the President of the IChemE and previously Executive Dean of Engineering and Physical Sciences at the University of Surrey. Jonathan is also a Fellow of the Royal Academy of Engineering and a Professor at the University of Birmingham.



### Sameer Dave

#### Senior Process Engineer

Chartered Chemical Engineer with over 29 years experience as a Process Engineer. 10 years Process/project experience in the Chemical Industry, and over 19 years experience in all phases of projects in the Oil and Gas, and Renewable/Transition Energy sectors.



### Gowtharaam Sivanathan

#### Lead Process Engineer

Gowtharaam was the Head of Process Engineering and Technology Development at Recycling Technologies Ltd. He spent 7+ years designing, developing and operating DeepTech Recycling's core technology.



### Dr. Andrew Cornish

#### Research Engineer

Andrew has a PhD in Inorganic Chemistry from the University of Nottingham. He has more than a decade experience working in Senior Research and Development Scientist roles at Johnson Matthey.



### Milan Banwaith

#### Process Development Engineer

Milan has an MSc in Chemical Engineering from Swansea University. He has more than half a decade experience working in oil refining and in operations at ADM and McCormick & Company.



# THANK YOU

---

## CONTACT US:

**DeepTech Recycling**  
Origin Building  
Wootton Science Park  
Oxfordshire  
OX13 6FD

marvine.besong@dtrecycling.co.uk  
+44 (0) 1865 602600

[www.deeptech-recycling.co.uk](http://www.deeptech-recycling.co.uk)



# WandaHealth

Intelligent Virtual Care  
Platform



*Tom Smith*

Chief Executive



# WandaHealth

**Intelligent virtual care platform - powered by biometric devices, actionable insights, and dedicated health coaches**



# Escalating Drug Spend For Payers

Health plans are facing unsustainable cost growth driven by chronic disease

## Rising Medication Dependence




76% of US Adults have at least one chronic condition.

66% of all US adults are on prescription drugs.

Drug regimens for chronic conditions are often for life.

42% of all US adults are currently obese.

## US Drug Spend \$4.5 T



Chronic conditions account for 90% of total spend (\$4.5T).

Cardiometabolic spend to reach \$200B by 2030.

GLP-1s account for half of all annual drug spend growth.

Annual cost of GLP-1s >\$10K pm.

## GLP-1 Demand



Expanded use into weight management.

Increased relapse upon discontinuation.

Combination therapies with higher price.

Employers and members want “fast-acting weight-loss” solutions.

## Showing Success



Payers lack an integrated way to support cardiometabolic disease and weight management.

Payers need to:

Demonstrate reduction in drug dependency.

Improve clinical outcomes.

Protect ROI.



# Intelligent Virtual Care Platform

Scalable cloud-based Software and Data-as-a-Service for health plans and providers.



AI-ready architecture that ingests disease-specific datasets to build predictive and personalised care models.

Co-Designed Mobile App - User engagement tools for capturing behavioural and symptomatic information and adherence insights.

Seamless 3rd-party integration with biometric and biomarker devices, integration with Apple and Google Health Kits.

Clinical Engagement Portal - Connects members with care teams through an integrated virtual consultation suite.

Insights Engine unifies all ingested data to surface actionable insights for Payers and Providers alike.





# Cardio Metabolic Management Programs

Intelligent management for improved adherence, clinical outcomes and ROI

Health Plan provides coverage for Cardiometabolic and Weight Management Drugs and Associated Programs



Device Shipped and Logistics updates for eligible Members



Member Onboarding  
App, Device initiation and Program Education by Wanda's Health Coaching



Data Capture  
Biometric, Biomarker, Behavioural and Symptomatic data is captured via Wanda Mobile App and connected devices



Clinical Engagement Portal  
Wanda Health Coaches review and manage member data



Virtual Consultations for Program and Medication Compliance



Program Monitoring Phases  
Wanda actively coaches' members through their personalised plan and goals



Insights Engine

Provides actionable reports at an individual or population level, for health coaches, benefits managers and health plans



Virtual Consultations for Program and Medication Compliance



Member reduces or increases their level of program support



# Wanda La Vista Mobile App

Improving member adherence through engagement

Apple and Google Health kit integrations

Biometric tabs, charts and notes

Personalised daily check-ins and tips

Virtual consultations with health coaches



Food Logging with photo capture feature

Meal planning, restaurant search and recommendations

Gamification of care plan and progress tracking

Multiple cardiometabolic disease programmes





# Wanda Insights Engine

Actionable Intelligence, demonstrable success

➔ A unified Reporting and Analytics layer that transforms all platform, device and coaching data into clear, actionable insights.

➔ User based reporting for different stakeholders.

➔ Individual, program or population level reporting.


➔ Medication utilisation and trajectory reporting.

➔ Program monitoring reporting.

➔ Health outcome measures trajectory.

➔ Lifestyle and coach impact reporting.

➔ Off ramps and ROI.





# Commercial Success

Successfully launched our GLP-1 weight management program.

Expanded partnerships with PBMs and multiple health plans.

Released our insights engine.

Launch of our new cardio metabolic mobile app.

Out-competed several billion dollar competitors to win contracts.

Exponential double digit month on month growth.

> \$5 M ARR by the end of 2026.





# Closing Remarks

**Intelligent Virtual Care Platform unifying biometric behavioural and connected device data with a dedicated coaching team.**

**Reshaping Virtual Care - Personalised insights, proactive support and lifestyle change.**

**Best in-class mobile app, Clinical Engagement Portal and Insights Engine.**

**Large exponentially growing market places - Chronic disease management, GLP-1 and remote monitoring.**

**Rapid exponential commercial traction and success.**



**Thank you**

**Any Questions?**

# EMV CAPITAL PLC

## JOIN OUR COMMUNITY

Follow EMV Capital plc on [LinkedIn](#) & [Twitter](#)

25-28 Old Burlington Street, London W1S 3AN

[www.emvcapital.com](http://www.emvcapital.com)

